Abstract: An enteral dosing control coupling comprising a cylindrical collar defining a hollow internal chamber and a lumen extension tip projecting axially into the internal chamber, the lumen extension tip defining an internal lumen extending therethrough. In example forms, the lumen extension tip is integrally formed with the cylindrical collar. In other example forms, the lumen extension tip is a separate piece and is removably engageable within the cylindrical collar. In some example forms, the present invention relates to syringes, connectors, couplings, etc. having ISO 80369-3 formatted couplings. In other example forms, the present invention relates to connectors, couplings, etc. for adapting coupling formats other than the ISO 80369-3 coupling format to the ISO 80369-3 coupling format.

Abstract: An embodiment according to the present invention provides a dental gypsum powder including a hemihydrate gypsum and a water-reducing agent, wherein the mass ratio of the water-reducing agent to the hemihydrate gypsum is 0.1 to 1%, the content of particles having a particle diameter of 10 ?m or less is 15 to 35 volume %, the content of particles having a particle diameter of 20 ?m or less is 40 to 55 volume %, and the content of particles having a particle diameter of 30 ?m or less is 55 to 75 volume %.

Abstract: A powder-containing composition contains an aqueous solvent, a cationic polymer that is present in the aqueous solvent and a powder that bears a negative charge on a surface in the aqueous solvent and has a BET specific surface area of less than 50 m2/g. A ratio of the mass in the composition of the cationic polymer to a total surface area in the composition of the powder is 1 ?g/m2 to 100,000 ?g/m2.

Abstract: A method of treating skin is disclosed. The method can include topically applying to a peron's skin a composition comprising 0.0001% to 5% w/w of a hydrolyzed algae extract comprising exopolysaccharides from Halymenia durvillei, and 0.0001% to 5% w/w of a saccharide isomerate comprising an exopolysaccharide synthesized by Vibrio alginolyticus, wherein at least one of skin permeability is decreased, filaggrin production is increased, skin moisture is increased, occludin production is increased, or TNF? production is inhibited in the skin.

Abstract: Cosmetic O/W emulsion containing 4-(tert.-butyl)-4?-methoxydibenzoylmethane, at least 90% of the oil droplets in the emulsion having a size (diameter) of less than 8 ?m.

Abstract: The invention relates to a method of making a personal care composition, the method comprising steps of: providing a mixer comprising a housing comprising a first fluid inlet, a second inlet, and a fluid outlet, the mixer further rotor rotatably connected with the housing, the rotor comprising blades positioned within the housing to define cells between neighboring blades and the housing; preparing a personal care chassis base comprising surfactants and water; preparing a microcapsule composition comprising microcapsules, and air; advancing personal care chassis base along a flow path from the first fluid inlet toward the fluid outlet; transferring the microcapsule composition from the second inlet to the flow path by rotating the rotor; directing air in the microcapsule composition from inside the cells toward the second inlet; combining the microcapsule composition with the personal care chassis base to form the personal care composition; and advancing the personal care composition from the outlet.

Abstract: The present specification discloses a composition comprising, consisting essentially of, or consisting of one or more grip enhancers, one or more hydrophilic clays, and/or one or more polysaccharides, kits comprising, consisting essentially of, or consisting of a disclosed composition, methods and uses to improve the grip capacity of an individual by applying a disclosed composition, and methods and uses to improve the grip capacity of an object by applying a disclosed composition.

Abstract: The present disclosure provides methods for using anthranilic acid (2-AA) blocked by tertbutyloxycarbonyl (Boc) groups in protocols for labeling glycans for analysis, and kits providing 2-AA-Boc and acids for unblocking blocked 2-AA for use in glycan labeling and analysis.

Abstract: The present invention relates to topical compositions comprising at least one liquid UV-filter and a nano-sized 1,4-di(benzoxazol-2?-yl)benzene.

Abstract: The present invention relates to novel cosmetic and therapeutic uses of one or more compounds of the general formula (1) as described herein. Furthermore, the present invention relates to compositions (products or, respectively, formulations), in particular for topical administration, preferably cosmetic or pharmaceutical compositions, comprising or consisting of compound(s) of formula (1) and one or more cosmetically and/or pharmaceutically acceptable carriers. The present invention also relates to novel uses of such N compositions according to the invention.

Abstract: The present invention belongs to the cosmetic field and relates to the use of an oil having a dielectric constant of at least 4.0 in a cosmetic composition to allow for a quick evaporation of water and/sweat from the skin, on which the cosmetic composition was applied to.

Abstract: The present invention relates to ethyl cyclooct-3/4-ene-1-carboxylates, and to a process of making the same. The invention further refers to flavour and fragrance compositions comprising them.

Abstract: The present specification provides a composition for the prevention or treatment of skin infection which has an excellent treatment effect on skin infection and causes less side effects. A pharmaceutical composition or a cosmetic composition for the prevention or treatment of skin infection of the present invention comprises terbinafine hydrochlodie, chlorhexidine gluconate, and ciclopirox olamine.

Abstract: The invention relates to stable, mild and moisturizing lamellar liquid cleansing compositions which possess a lotion-like appearance conveying signals of enhanced moisturization. However, these liquids often are either unstable or cause poor lather production and other sensory deficits The use of a specific ratio of total acyl isethionates to acyl glutamates or other divalent anionic surfactant in a structured liquid product improve stability and lather production, mildness and acceptable odor.

Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

Abstract: The present disclosure provides an eyeliner product and a method thereof. The eyeliner product includes components as follows: foundation makeup liquid, acrylic acid octyl acrylamide copolymer or propylene ester octyl acrylamide copolymer, tackifier, vegetable gum, and surface modifier. The eyeliner product is provided by weight. The acrylic acid octyl acrylamide copolymer or the propylene ester octyl acrylamide copolymer is provided in an amount ranging from 10-11 parts. The tackifier is provided in an amount ranging from 1-3 parts. The vegetable gum is provided in an amount ranging from 6-12 parts. The surface modifier is provided in an amount ranging from 0.1-2 parts. And the vegetable gum is starch glue.

Abstract: A dispersible powder includes a powder treated with a surface treatment agent, and the surface treatment agent contains a (meth)acrylic polymer having a repeating unit with a phosphorylcholine group. Thus, provided are: a dispersible powder having excellent dispersibility in an aqueous medium and high dispersion stability; and a cosmetic blended with this powder, the cosmetic being capable of forming a uniform cosmetic film and having favorable spreadability upon application, stretchability, adhesiveness, and feeling on use as well as high stability.

Abstract: A volatile oil composition includes a vehicle and a silicone elastomer, wherein the vehicle is a volatile oily composition of (a) from 50 to 100% by weight of a mixture of linear paraffins including (i) 90 to 99% by weight of at least one linear paraffin selected from C8, C10, C12 paraffins and mixtures thereof, and (ii) 1 to 10% by weight of a C14 linear paraffin, and (b) from 0 to 50% by weight of at least one non-volatile oil. The composition may be used in cosmetic compositions such as for making up and/or caring for and/or protecting skin, lips, eyelashes and/or nails, and in antiperspirant/deodorant compositions.

Abstract: A cosmetic ink composition comprises a particulate material, a (meth)acrylic acid homopolymer or salt thereof, and a rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The (meth)acrylic acid homopolymer or salt thereof can have a weight average molecular weight of less than about 20,000 daltons. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a first dynamic viscosity of greater than about 1,100 cP at a shear rate of 0.1 sec?1 measured at 25° C. and a second dynamic viscosity of less than about 100 cP at a shear rate of 1,000 sec?1 measured at 25° C.

Abstract: The present invention relates to a composition such as an anhydrous gel, and its use for example as a cosmetic base, comprising a silicone-based excipient and one or more carrier oils, and methods of administering the composition to a subject.

Abstract: Polymers comprising at least one cationic functional group and at least one ultraviolet light-absorbing compound are disclosed herein. The polymers exhibit ultraviolet light-absorbing properties and may be used in sunscreen compositions for skin and/or hair.

Abstract: The present invention primarily relates to the use of a composition consisting of or comprising an extract of Isochrysis sp., preferably of Tahitian Isochrysis, for influencing or modifying the hair fiber of human hair, wherein the use is not a use for influencing or modifying growth of human hair or pigmentation of human hair. The invention furthermore relates to a method for influencing or modifying the hair fiber of human hair consisting of or comprising the steps as defined herein.

Abstract: A pulp and skin extract from dried, seed-free Myrciaria dubia fruit. The Myrciaria dubia fruit has a maturity of at least 70%, a soluble solids/acidity ratio between 2.5 and 3, and it is rich in organic acids. The extract is obtained by solid-liquid extraction in a hydro-polyalcohol solvent selected from a hydro-glycerol and/or hydro-gylcolic solvent under conventional agitation or with ultrasound. The extract is an active in cosmetic compositions, which reduce the signs of skin fatigue.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Aspects described herein relate to improved compositions and methods for transdermal and/or dermal delivery of lipophilic active agents, particularly without the need for added penetration enhancers.

Abstract: A transdermal composition comprising ibuprofen or salts thereof and a gelling agent which can be used for the treatment of such disorders as pain, inflammation, arthritis, muscle spasm and associated symptoms in humans and animals.

Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

Abstract: Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing and suspending agents (of which one is a non-ionic polyoxyethlene-polyoxypropylene block copolymer), and a carrier. Methods for fabricating the compositions and using them are also described.

Abstract: Methods and compositions for treating conditions including autoimmune uveitis using inhibitors of Colony stimulating factor 1 receptor (CSF1R).

Abstract: A drink composition for preventing alcohol-induced liver damage, which is effective for hangover relief and which contains 2 to 4 wt % of black ginseng, 4 to 7 wt % of blueberry, 0.3 to 1 wt % of dry yeast, 0.5 to 1.5 wt % of jujube pulp, and 2 to 4 wt % of oriental raisin tree fruit and is produced by hot-water extraction using the remaining wt % of purified water. The composition has a liver damage suppressing effect, reduces hepatitis activity index, and thus may be used as a composition capable of preventing or treating various liver diseases. Furthermore, it has very excellent effects on alcohol degradation and acetaldehyde degradation, alleviates headache and vomiting symptoms the next day after drinking, and thus is also very useful as a composition for liver protection or hangover relief, which is taken before and after alcohol drinking.

Abstract: An effervescent powder product containing cannabinoids, terpenes and cannabidiol (CBD) and a process for producing an effervescent supplement powder. The effervescent powder having a density that enables the effervescent powder to break apart and/or dissolve when it is added to or submerged in any liquid, including non-carbonated and carbonated liquids, with or without stirring. The floating delivery system yields an effervescent powder bulk density that is lower than the gastric fluid and allows the active components to remain buoyant for extended time periods without affecting the rate of gastric emptying.

Abstract: A process for producing a solid dispersion of a material by spraying the material onto a fluidized cloud of carrier particles in a fluid bed. The fluidized cloud of carrier particles is formed by adding a solid or liquid carrier to a fluid bed. The material to be sprayed is in a liquid or gas form. The process is especially applicable to the formation of amorphous solid powder pharmaceutical ingredients.

Abstract: Provided is an emulsion composition that is capable of enhancing systemic absorption for various carotenoids, well compatible with soft capsules, and capable of being formulated into a soft capsule formulation, and that homogeneously disperses raw materials including carotenoids and emulsifiers in the soft capsule formulation. An emulsion composition containing a carotenoid, and two or more specific emulsifiers selected from the group consisting of tetraglycerin monooleate, decaglycerin monolaurate, sucrose stearate, and sucrose laurate.

Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Abstract: Compositions and methods comprising asymmetrical artificial antigen presenting cells (aAPCs) are disclosed. The non-spherical aAPCs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy.

Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.

Abstract: The invention provides a tablet that contains free-form arginine at a high content, suppresses cracking and collapse due to moisture absorption, is superior in preservation stability and permits convenient production. The tablet contains free-form arginine at a concentration of not less than 5 mass % of the total amount of the tablet and can be obtained by compression molding free-form arginine dried by a spray dry method.

Abstract: Articles and methods for delivering a therapeutic agent to a subject are described. These articles and methods may be useful, in some cases, for the delivery of therapeutic agents to the colon of a subject. In some embodiments, an article is configured to release a secretion inducing agent e.g., to stimulate the release of intestinal fluids. The article, in some embodiments, comprises a therapeutic agent such that the stimulated release of intestinal fluid increases the amount of therapeutic agent available for absorption by the colon. For example, in some embodiments, the articles and methods described herein advantageously promote increased absorption of therapeutic agents in subjects as compared to traditionally administered therapeutic agents without additional components such as a secretion inducing agent. In some embodiments, articles and methods described herein may increase the motility of the colon of a subject.

Abstract: There is provided low-substituted hydroxypropyl cellulose (L-HPC) having good bindability, anti-capping performance and disintegratability. More specifically, there are provided L-HPC having a hydroxypropoxy group content of 5 to 16% by mass and a volume fraction of long fibrous particles of more than 50.0% relative to all of L-HPC particles which are classified, on a basis of dynamic image analysis, into fine particles, spherical particles, the long fibrous particles and short fibrous particles; and a solid preparation containing the L-HPC.

Abstract: Enteric softgel capsules comprise a fill material and an enteric shell composition, characterized in that the enteric nature of the capsules may be achieved without an enteric coating or added conventional enteric polymers.

Abstract: A pharmaceutical abuse deterrent composition and method of making the same is described in the present invention. A pharmaceutical abuse deterrent composition is constructed in one strength or more than one strength, wherein each strength in alone or in combination with another strength has a unique overdose prevention features. A pharmaceutical abuse deterrent composition is constructed in one strength or more than one strength, wherein each strength has resistant to physical tampering and chemical tampering.

Abstract: The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 ?g/mL at pH 6.8.

Abstract: A method includes delivering a composition to a tissue site within a volume of tissue; and at least one of monitoring the effect of the composition on an electrophysiological state of a region in the volume of tissue and monitoring the migration of the composition in the region after delivery to the site; wherein the composition comprises an ablative agent for performing a treatment within a body of a subject and an excipient for limiting migration of at least one of the composition and the ablative agent within the body after delivery to the tissue site.

Abstract: This invention discloses a nutritional composition of matter that effectively provide a nootropic effect beyond the effects simple obtain by cannabinoids alone. Effectively reduce anxiety due to ingestion of xanthines containing oral products. Similarly reduce the side effects associated with the exogenous ingestion of yohimbine and its derivatives.

Abstract: The present disclosure provides ophthalmic compositions containing resveratrol. Also provided are methods of using ophthalmic resveratrol compositions to treat acute ocular pain, chronic ocular pain, dry eye disease, and/or photophobia.

Abstract: The present disclosure concerns methods and formulations for delivery of hydrophobic agents (such as ubiquinone or poorly soluble drugs) for therapeutic and bioanalytical use. It further concerns use of lipopeptides (e.g. caspofungin) or surfactants to solubilize hydrophobic agents and thus increase their bioavailability. Also described are therapeutic methods for the treatment of conditions that benefit from such hydrophobic agents. The present disclosure further relates to methods of identifying drug candidates for treatment of ubiquinone deficiency.

Abstract: A reduced coenzyme Q10-containing composition has high water solubility and excellent storage stability. A powder composition contains the reduced coenzyme Q10, starch octenylsuccinate, and gum Arabic. A method of producing the powder composition includes homogenizing the ingredients in water to obtain an emulsion composition; and drying the composition.

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract: Formulations for treating ocular surface diseases, such as dry eye disease, and related methods are disclosed. The formulations include and effective amount of ambroxol or a chemical derivative thereof (for example, bromhexine) that may be dispersed in a carrier and may optionally include a biocompatible polymer to provide extended release properties.

Abstract: The present disclosure relates to nanoemulsion compositions with certain surfactant blend ratios that impart enhanced permeability. Such compositions are useful for topical, mucosal and intranasal applications and allow for the greater delivery of one or more active agents to the application site to prevent infection by a microorganism.